IBRX-042

· ImmunityBio, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for IBRX-042, covering 2025-10-20 to 2025-10-20. Get the full timeline:

Most recent: Clinical Trial Update: IBRX-042 In Participants With HPV-Associated Tumors [Phase 1]